Lysophosphatidic acid (LPA) metabolism (LPA metabolism)

Lysophosphatidic acid (LPA) metabolism refers to the enzymatic network and signaling axis involving the production, degradation, and receptor-mediated actions of the bioactive lipid LPA. The pathway is primarily initiated by the secreted enzyme Autotaxin (ATX), which possesses lysophospholipase D activity to convert lysophosphatidylcholine into LPA in the extracellular space (PMID: 12105214). LPA subsequently signals through a series of six distinct G protein-coupled receptors (LPA1-6) to drive essential cellular processes such as proliferation, survival, and migration (PMID: 20581098). Dysregulation of this metabolism, particularly through the overproduction of LPA or increased receptor sensitivity, is a hallmark of several fibroproliferative and oncogenic diseases, most notably idiopathic pulmonary fibrosis and metastatic cancer (PMID: 18193031). Therapeutic strategies targeting this pathway include the development of Autotaxin inhibitors to lower systemic LPA levels and selective LPA receptor antagonists to block specific pathological signaling cascades (PMID: 31005427). While the pathway is a promising therapeutic target, challenges include maintaining physiological LPA functions such as wound healing and vascular stability while inhibiting its disease-driving effects.

Other names

Autotaxin-LPA axisLPA signaling pathwayATX-LPA pathwayLysophosphatidic acid signaling

Inhibition of Autotaxin (ENPP2) to reduce LPA synthesis and antagonism of LPA receptors (primarily LPA1) to block downstream signaling cascades.